“Up to twenty percent of children are affected by atopic dermatitis and there remains a significant unmet need for new treatment options that may improve their care,” said
The approval allows Kalydeco to be used for the treatment of children and adolescents with CF aged between six months and older with a weight of at least
The collaboration will evaluate Lyvgen’s LVGN6051, a second generation 4-1BB (CD137) agonist antibody, in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in a Phase 1 study in adult
The partnership will assess the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product DRibble Platform Vaccine 001(DPV-001) in combination with BMS’ anti-OX40 (BMS-986178) combined with sequenced administration
“With the FDA’s expanded definition of Critical COVID-19 to include patients on all forms of ventilation and the recent trend at leading hospitals that avoids mechanical ventilators whenever
Eli Lilly’s partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralising antibody treatment, known as JS016, to treat Covid-19 disease. Junshi
The peer-reviewed case series of 19 hospitalised patients with COVID-19 disease and severe hypoxia and/or inflammation is a collaboration from investigators across the US, including AstraZeneca scientists, and
The regulator has approved a supplemental new drug application (sNDA) for Recarbrio to treat patients 18 years of age and older with HABP/VABP caused due to susceptible Gram-negative
Since March, MTx has selected the most promising donors from hundreds of Swiss COVID-19 patients. The selection criteria identified patients who had demonstrated a clinical course of COVID-19
The partnership will combine Accent’s expertise in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s advanced knowledge in oncology. Accent Therapeutics CEO Shakti Narayan
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.